1.61
Inovio Pharmaceuticals Inc stock is traded at $1.61, with a volume of 358.62K.
It is up +1.90% in the last 24 hours and up +0.63% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$1.58
Open:
$1.58
24h Volume:
358.62K
Relative Volume:
0.24
Market Cap:
$110.61M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.2644
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
-3.01%
1M Performance:
+0.63%
6M Performance:
-5.29%
1Y Performance:
-24.41%
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
INO
Inovio Pharmaceuticals Inc
|
1.61 | 108.55M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Plug Power Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PLUG - GlobeNewswire Inc.
ROSEN, A LEADING LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
INO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors ... - bdtonline.com
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionINO - ACCESS Newswire
DEADLINE ALERT for TCPC, ORCL, PSFE, and INO: The Law - GlobeNewswire
Forecast Cut: What’s next for Inovio Pharmaceuticals Inc. stockJuly 2025 Highlights & Daily Market Momentum Tracking - mfd.ru
2026-02-13 | INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:INO | Press Release - Stockhouse
ROSEN, LEADING INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionINO - ACCESS Newswire
INO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - ACCESS Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain OfficersINO - PR Newswire
Securities Fraud Investigation Into Inovio Pharmaceuticals, Inc. (INO) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - marketscreener.com
Inovio Pharmaceuticals Under Investigation for Possible Securities Law Violations - Intellectia AI
FinancialContentInovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
Securities Fraud Investigation Into Inovio Pharmaceuticals, Inc. (INO) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
Portnoy Law Firm Announces Class Action on Behalf of Inovio Pharmaceuticals, Inc. Investors - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Inovio - GlobeNewswire
INOVIO to Participate in Multiple Scientific and Investor Conferences - Intellectia AI
Published on: 2026-02-12 16:56:02 - mfd.ru
INOVIO to Participate in Upcoming Scientific and Investor Conferences - Finviz
Inovio Pharmaceuticals Faces Class Action for Securities Fraud - Intellectia AI
User - The Chronicle-Journal
2026-02-12 | INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:INO | Press Release - Stockhouse
Is Inovio Pharmaceuticals Inc. stock good for income investorsQuarterly Portfolio Review & Breakout Confirmation Alerts - mfd.ru
INOVIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inovio - GlobeNewswire
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - The Malaysian Reserve
Will Inovio Pharmaceuticals Inc. stock see PE expansion2025 Investor Takeaways & Expert Curated Trade Setup Alerts - mfd.ru
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, I - GuruFocus
IINO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Inovio Pharmaceuticals, Inc. - PR Newswire
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit - InsideNoVa.com
INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DNA Nanotechnology Market Growth in Future Scope 2026-2033 - openPR.com
Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders to Contact the Firm for - PharmiWeb.com
Rosen Law Firm Urges Inovio Paysafe Limited (NASDAQ: PSFE) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
Inovio Pharmaceuticals Faces Class Action for Misleading Investors - Intellectia AI
Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders to Contact the Firm for Information About Their Rights - bdtonline.com
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements - Intellectia AI
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuti - PharmiWeb.com
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit - Business Wire
Aug Sentiment: Is Inovio Pharmaceuticals Incs ROE strong enoughJuly 2025 Opening Moves & Risk Managed Investment Strategies - baoquankhu1.vn
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Stock Report: Is Inovio Pharmaceuticals Incs ROE strong enoughTrade Performance Summary & High Conviction Trade Alerts - baoquankhu1.vn
Risk Recap: Is Inovio Pharmaceuticals Inc a turnaround storyRate Cut & Daily Profit Focused Stock Screening - baoquankhu1.vn
Inovio Pharmaceuticals (INO) Price Target Increased by 12.14% to 8.73 - Nasdaq
Pomerantz LLP Investigates Inovio Securities Fraud Claims - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - GlobeNewswire Inc.
Is Inovio Pharmaceuticals Inc a potential multi baggerEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn
Market Trends: What is the implied volatility of Match Group IncMarket Weekly Review & Comprehensive Market Scan Reports - baoquankhu1.vn
Guidance Update: Is Inovio Pharmaceuticals Inc a top pick in the sectorForecast Cut & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Is Inovio Pharmaceuticals Inc.’s ROIC above industry average2025 Dividend Review & Free Long-Term Investment Growth Plans - mfd.ru
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):